AstraZeneca PLC Earnings Recaps
Q3 2025
Nov 8, 2025
AstraZeneca continues its strong growth trajectory, reporting an 11% revenue increase year-to-date, fueled by robust demand for its innovative drugs and significant advancements in its pipeline.
Key takeaways
- Core EPS rose by 15%, reflecting sustained operational momentum.
- The company achieved 31 regulatory approvals this year, underscoring an accelerating pipeline.
- Growth was broad-based, with oncology revenue up 16% and substantial advances in Biopharmaceuticals and Rare Diseases.
- AstraZeneca secured a landmark pricing agreement in the U.S., expected to enhance accessibility and market stability.
- Strong performance across key geographies, particularly the U.S. and emerging markets, which saw revenue increases of 11% and 21%, respectively.